Literature DB >> 28287892

Landscaping a chromatin response to MEK inhibition.

Jon S Zawistowski1, Daniel R Goulet1, Gary L Johnson1.   

Abstract

Entities:  

Keywords:  MEK inhibition; P-TEFb; adaptive transcriptional response; enhancer remodeling; epigenomic landscape

Mesh：

Substances：

Year:  2017        PMID： 28287892      PMCID： PMC5405712          DOI： 10.1080/15384101.2017.1302232

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  7 in total

1.  Deregulation of the Ras-Erk Signaling Axis Modulates the Enhancer Landscape.

Authors:  Behnam Nabet; Pilib Ó Broin; Jaime M Reyes; Kevin Shieh; Charles Y Lin; Christine M Will; Relja Popovic; Teresa Ezponda; James E Bradner; Aaron A Golden; Jonathan D Licht
Journal:  Cell Rep       Date:  2015-08-13       Impact factor: 9.423

2.  NF-κB directs dynamic super enhancer formation in inflammation and atherogenesis.

Authors:  Jonathan D Brown; Charles Y Lin; Qiong Duan; Gabriel Griffin; Alexander Federation; Ronald M Paranal; Steven Bair; Gail Newton; Andrew Lichtman; Andrew Kung; Tianlun Yang; Hong Wang; Francis W Luscinskas; Kevin Croce; James E Bradner; Jorge Plutzky
Journal:  Mol Cell       Date:  2014-09-25       Impact factor: 17.970

3.  Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.

Authors:  Jon S Zawistowski; Samantha M Bevill; Daniel R Goulet; Timothy J Stuhlmiller; Adriana S Beltran; Jose F Olivares-Quintero; Darshan Singh; Noah Sciaky; Joel S Parker; Naim U Rashid; Xin Chen; James S Duncan; Martin C Whittle; Steven P Angus; Sara Hanna Velarde; Brian T Golitz; Xiaping He; Charlene Santos; David B Darr; Kristalyn Gallagher; Lee M Graves; Charles M Perou; Lisa A Carey; H Shelton Earp; Gary L Johnson
Journal:  Cancer Discov       Date:  2017-01-20       Impact factor: 39.397

4.  Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains.

Authors:  Timothy J Stuhlmiller; Samantha M Miller; Jon S Zawistowski; Kazuhiro Nakamura; Adriana S Beltran; James S Duncan; Steven P Angus; Kyla A L Collins; Deborah A Granger; Rachel A Reuther; Lee M Graves; Shawn M Gomez; Pei-Fen Kuan; Joel S Parker; Xin Chen; Noah Sciaky; Lisa A Carey; H Shelton Earp; Jian Jin; Gary L Johnson
Journal:  Cell Rep       Date:  2015-04-09       Impact factor: 9.423

5.  Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy.

Authors:  Elias E Stratikopoulos; Meaghan Dendy; Matthias Szabolcs; Alan J Khaykin; Celine Lefebvre; Ming-Ming Zhou; Ramon Parsons
Journal:  Cancer Cell       Date:  2015-06-08       Impact factor: 31.743

6.  Selective inhibition of tumor oncogenes by disruption of super-enhancers.

Authors:  Jakob Lovén; Heather A Hoke; Charles Y Lin; Ashley Lau; David A Orlando; Christopher R Vakoc; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

7.  Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.

Authors:  James S Duncan; Martin C Whittle; Kazuhiro Nakamura; Amy N Abell; Alicia A Midland; Jon S Zawistowski; Nancy L Johnson; Deborah A Granger; Nicole Vincent Jordan; David B Darr; Jerry Usary; Pei-Fen Kuan; David M Smalley; Ben Major; Xiaping He; Katherine A Hoadley; Bing Zhou; Norman E Sharpless; Charles M Perou; William Y Kim; Shawn M Gomez; Xin Chen; Jian Jin; Stephen V Frye; H Shelton Earp; Lee M Graves; Gary L Johnson
Journal:  Cell       Date:  2012-04-13       Impact factor: 41.582
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.